MRT-3 free antigen testing ends on June 30 | Inquirer News

MRT-3 free antigen testing ends on June 30

By: - Reporter / @zacariansINQ
/ 07:02 PM June 23, 2022

New train coaches of MRT-3

New train coaches of MRT-3

MANILA, Philippines — The Department of Transportation’s (DOTr) free antigen testing for COVID-19 in Metro Rail Transit Line 3 (MRT-3) will end on June 30, the railway management said Thursday.

“Huling araw ng pamamahagi ng LIBRENG ANTIGEN TESTING ng pamunuan ng MRT-3 para sa mga boluntaryong pasahero nito sa ika-30 ng Hunyo, 2022,” said the management of MRT-3 in an advisory on Thursday.

ADVERTISEMENT

(Last day of distribution of free antigen testing by the MRT-3 management for its volunteer passengers on June 30, 2022.)

FEATURED STORIES

The management said commuters could avail themselves of free antigen testing in North Avenue stations, Shaw Boulevard stations from 7 a.m. to 8 a.m., and Cubao and Shaw stations from 4:00 p.m. to 5:00 p.m.

It can be recalled that the DOTr started its free random antigen screenings for MRT-3 from January 11 to 31, before resuming on Feb. 2.

“Simula ika-28 ng Enero, 2022, walang anumang kaso ng nagpositibo sa COVID-19 ang naitala sa antigen testing para sa mga pasahero,” the MRT-3 management said.

(Since Jan. 28, no cases of COVID-19 positive have been recorded in antigen testing for passengers.)

Meanwhile, the MRT-3 management also announced that the railway system’s free ride program will continue until June 30.

RELATED STORIES:

Free rides at Edsa Carousel will continue until July 31

Over 71 million have used free transport service since April

JMS/abc
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: antigen test, DoTr, free MRT-3 rides

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.